A modified human ELISPOT assay to detect specific responses to primary tumor cell targets
<p>Abstract</p> <p>Background</p> <p>The desired outcome of cancer vaccination is to induce a potent T cell response which can specifically recognize and eliminate autologous tumor cells <it>in vivo</it>. Accordingly, immunological assays that demonstrate re...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2004-03-01
|
| Series: | Journal of Translational Medicine |
| Online Access: | http://www.translational-medicine.com/content/2/1/9 |
| _version_ | 1818524621682507776 |
|---|---|
| author | Kwak Larry W Baseler Michael Troke Angela Ulderich Tracy Shafer-Weaver Kimberly A Strobl Susan L Malyguine Anatoli Neelapu Sattva S |
| author_facet | Kwak Larry W Baseler Michael Troke Angela Ulderich Tracy Shafer-Weaver Kimberly A Strobl Susan L Malyguine Anatoli Neelapu Sattva S |
| author_sort | Kwak Larry W |
| collection | DOAJ |
| description | <p>Abstract</p> <p>Background</p> <p>The desired outcome of cancer vaccination is to induce a potent T cell response which can specifically recognize and eliminate autologous tumor cells <it>in vivo</it>. Accordingly, immunological assays that demonstrate recognition of native tumor cells (tumor-specific) may be more clinically relevant than assays that demonstrate recognition of tumor protein or peptide (antigen-specific).</p> <p>Methods</p> <p>Towards this goal, we adapted the IFN-γ ELISPOT assay to measure immune responses against autologous primary tumor cells in vaccinated cancer patients. As a model system to develop the assay, we utilized peripheral blood mononuclear cells (PBMC) directly isolated from follicular lymphoma patients vaccinated with tumor-derived idiotype protein.</p> <p>Results</p> <p>After optimizing several variables, we demonstrated that the modified IFN-γ ELISPOT assay could be used to reliably and reproducibly determine the tumor-reactive T cell frequency in the PBMC of these patients. The precursor frequency of tumor-reactive T cells was significantly higher in the postvaccine PBMC, compared with prevaccine samples in all patients tested. Furthermore, the specificity of these T cells was established by the lack of reactivity against autologous normal B cells.</p> <p>Conclusions</p> <p>These results demonstrate the feasibility of quantitating tumor-specific T cell responses when autologous, primary tumor cells are available as targets.</p> |
| first_indexed | 2024-12-11T05:59:25Z |
| format | Article |
| id | doaj.art-fb376883a93042de9a5b0b8026fb759e |
| institution | Directory Open Access Journal |
| issn | 1479-5876 |
| language | English |
| last_indexed | 2024-12-11T05:59:25Z |
| publishDate | 2004-03-01 |
| publisher | BMC |
| record_format | Article |
| series | Journal of Translational Medicine |
| spelling | doaj.art-fb376883a93042de9a5b0b8026fb759e2022-12-22T01:18:34ZengBMCJournal of Translational Medicine1479-58762004-03-0121910.1186/1479-5876-2-9A modified human ELISPOT assay to detect specific responses to primary tumor cell targetsKwak Larry WBaseler MichaelTroke AngelaUlderich TracyShafer-Weaver Kimberly AStrobl Susan LMalyguine AnatoliNeelapu Sattva S<p>Abstract</p> <p>Background</p> <p>The desired outcome of cancer vaccination is to induce a potent T cell response which can specifically recognize and eliminate autologous tumor cells <it>in vivo</it>. Accordingly, immunological assays that demonstrate recognition of native tumor cells (tumor-specific) may be more clinically relevant than assays that demonstrate recognition of tumor protein or peptide (antigen-specific).</p> <p>Methods</p> <p>Towards this goal, we adapted the IFN-γ ELISPOT assay to measure immune responses against autologous primary tumor cells in vaccinated cancer patients. As a model system to develop the assay, we utilized peripheral blood mononuclear cells (PBMC) directly isolated from follicular lymphoma patients vaccinated with tumor-derived idiotype protein.</p> <p>Results</p> <p>After optimizing several variables, we demonstrated that the modified IFN-γ ELISPOT assay could be used to reliably and reproducibly determine the tumor-reactive T cell frequency in the PBMC of these patients. The precursor frequency of tumor-reactive T cells was significantly higher in the postvaccine PBMC, compared with prevaccine samples in all patients tested. Furthermore, the specificity of these T cells was established by the lack of reactivity against autologous normal B cells.</p> <p>Conclusions</p> <p>These results demonstrate the feasibility of quantitating tumor-specific T cell responses when autologous, primary tumor cells are available as targets.</p>http://www.translational-medicine.com/content/2/1/9 |
| spellingShingle | Kwak Larry W Baseler Michael Troke Angela Ulderich Tracy Shafer-Weaver Kimberly A Strobl Susan L Malyguine Anatoli Neelapu Sattva S A modified human ELISPOT assay to detect specific responses to primary tumor cell targets Journal of Translational Medicine |
| title | A modified human ELISPOT assay to detect specific responses to primary tumor cell targets |
| title_full | A modified human ELISPOT assay to detect specific responses to primary tumor cell targets |
| title_fullStr | A modified human ELISPOT assay to detect specific responses to primary tumor cell targets |
| title_full_unstemmed | A modified human ELISPOT assay to detect specific responses to primary tumor cell targets |
| title_short | A modified human ELISPOT assay to detect specific responses to primary tumor cell targets |
| title_sort | modified human elispot assay to detect specific responses to primary tumor cell targets |
| url | http://www.translational-medicine.com/content/2/1/9 |
| work_keys_str_mv | AT kwaklarryw amodifiedhumanelispotassaytodetectspecificresponsestoprimarytumorcelltargets AT baselermichael amodifiedhumanelispotassaytodetectspecificresponsestoprimarytumorcelltargets AT trokeangela amodifiedhumanelispotassaytodetectspecificresponsestoprimarytumorcelltargets AT ulderichtracy amodifiedhumanelispotassaytodetectspecificresponsestoprimarytumorcelltargets AT shaferweaverkimberlya amodifiedhumanelispotassaytodetectspecificresponsestoprimarytumorcelltargets AT stroblsusanl amodifiedhumanelispotassaytodetectspecificresponsestoprimarytumorcelltargets AT malyguineanatoli amodifiedhumanelispotassaytodetectspecificresponsestoprimarytumorcelltargets AT neelapusattvas amodifiedhumanelispotassaytodetectspecificresponsestoprimarytumorcelltargets AT kwaklarryw modifiedhumanelispotassaytodetectspecificresponsestoprimarytumorcelltargets AT baselermichael modifiedhumanelispotassaytodetectspecificresponsestoprimarytumorcelltargets AT trokeangela modifiedhumanelispotassaytodetectspecificresponsestoprimarytumorcelltargets AT ulderichtracy modifiedhumanelispotassaytodetectspecificresponsestoprimarytumorcelltargets AT shaferweaverkimberlya modifiedhumanelispotassaytodetectspecificresponsestoprimarytumorcelltargets AT stroblsusanl modifiedhumanelispotassaytodetectspecificresponsestoprimarytumorcelltargets AT malyguineanatoli modifiedhumanelispotassaytodetectspecificresponsestoprimarytumorcelltargets AT neelapusattvas modifiedhumanelispotassaytodetectspecificresponsestoprimarytumorcelltargets |